Article thumbnail

Computer applications for prediction of protein–protein interactions and rational drug design

By Solène Grosdidier, Max Totrov and Juan Fernández-Recio

Abstract

In recent years, protein–protein interactions are becoming the object of increasing attention in many different fields, such as structural biology, molecular biology, systems biology, and drug discovery. From a structural biology perspective, it would be desirable to integrate current efforts into the structural proteomics programs. Given that experimental determination of many protein–protein complex structures is highly challenging, and in the context of current high-performance computational capabilities, different computer tools are being developed to help in this task. Among them, computational docking aims to predict the structure of a protein–protein complex starting from the atomic coordinates of its individual components, and in recent years, a growing number of docking approaches are being reported with increased predictive capabilities. The improvement of speed and accuracy of these docking methods, together with the modeling of the interaction networks that regulate the most critical processes in a living organism, will be essential for computational proteomics. The ultimate goal is the rational design of drugs capable of specifically inhibiting or modifying protein–protein interactions of therapeutic significance. While rational design of protein–protein interaction inhibitors is at its very early stage, the first results are promising

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3169948
Provided by: PubMed Central

Suggested articles

Citations

  1. (2000). 2.8 program manual.
  2. (1998). A beta-sheet peptide inhibitor of E47 dimerization and DNA binding. Chem Biol.
  3. (1997). A calixarene with four peptide loops: an antibody mimic for recognition of protein surfaces. Angew Chem Ed Engl.
  4. (1999). A combined algorithm for genome-wide prediction of protein function.
  5. A comprehensive analysis of protein–protein interactions in Saccharomyces cerevisiae.
  6. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules.
  7. (1997). A computer screening approach to immunoglobulin superfamily structures and interactions: discovery of small non-peptidic CD4 inhibitors as novel immunotherapeutics.
  8. (2006). A database and tool, IM Browser, for exploring and integrating emerging gene and protein interaction data for Drosophila. BMC Bioinformatics.
  9. (2007). A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov.
  10. A fast method to predict protein interaction sites from sequences.
  11. A genomic approach of the hepatitis C virus generates a protein interaction map.
  12. A geometric approach to macromolecule-ligand interactions.
  13. (1995). A geometry-based suite of molecular docking processes.
  14. (2000). A high-throughput assay to identify compounds that can induce dimerization of the erythropoietin receptor. Anal Biochem.
  15. (1995). A hot spot of binding energy in a hormonereceptor interface.
  16. (1999). A method for computational combinatorial peptide design of inhibitors of Ras protein. Protein Eng.
  17. A multiple-start Monte Carlo docking method.
  18. A network of protein–protein interactions in yeast.
  19. (1999). A new potent HIV-1 reverse transcriptase inhibitor. A synthetic peptide derived from the interface subunit domains.
  20. (1998). A non-peptide compound which can mimic the effect of thrombopoietin via c-Mpl. FEBS Lett.
  21. A protein–protein docking benchmark.
  22. (2007). A proteome-wide protein interaction map for Campylobacter jejuni. Genome Biol.
  23. (1994). A role for surface hydrophobicity in protein–protein recognition. Protein Sci.
  24. A simple physical model for binding energy hot spots in protein–protein complexes.
  25. (1998). A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor.
  26. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix.
  27. (2007). Allosteric inhibition of the protein–protein interaction between the leukemia-associated proteins Runx1 and CBFbeta. Chem Biol.
  28. Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry.
  29. (1999). An analysis of conformational changes on protein–protein association: implications for predictive docking. Protein Eng.
  30. (1998). An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation. Nat Struct Biol.
  31. An inhibitor of Bcl-2 family proteins induces regression of solid tumours.
  32. An inhibitory monoclonal antibody binds at the turn of the helix-turn-helix motif in the N-terminal domain of HIV-1 integrase.
  33. (1988). An investigation of protein subunit and domain interfaces. Protein Eng.
  34. (1997). Analysis of protein–protein interaction sites using surface patches.
  35. (1999). Analysis of protein–protein interactions by mutagenesis: direct versus indirect effects. Protein Eng.
  36. (1998). Anatomy of hot spots in protein interfaces.
  37. (1998). Anatomy of protein pockets and cavities: measurement of binding site geometry and implications for ligand design. Protein Sci.
  38. (2000). Antagonists of protein–protein interactions. Chem Biol.
  39. Arg-Gly-Asp: a versatile cell recognition signal.
  40. ASEdb: a database of alanine mutations and their effects on the free energy of binding in protein interactions.
  41. (2008). Assembly of protein complexes by coexpression in prokaryotic and eukaryotic hosts: an overview. Methods Mol Biol.
  42. Assessment of blind predictions of protein–protein interactions: current status of docking methods.
  43. Assessment of CAPRI predictions in rounds 3–5 shows progress in docking procedures.
  44. Assigning protein functions by comparative genome analysis: protein phylogenetic profiles.
  45. Atomic solvation parameters in the analysis of protein–protein docking results. Protein Sci.
  46. ATTRACT: protein–protein docking in CAPRI using a reduced protein model.
  47. (1992). Automated docking with grid-based energy evaluation.
  48. (1999). Automatic extraction of biological information from scientific text: protein–protein interactions.
  49. (2000). Automatic extraction of protein interactions from scientific abstracts. Pac Symp Biocomput.
  50. (1994). Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins.
  51. BiGGER: a new (soft) docking algorithm for predicting protein interactions.
  52. (2001). BIND – The Biomolecular Interaction Network Database. Nucleic Acids Res.
  53. Binding site elucidation of hydantoin-based antagonists of LFA-1 using multidisciplinary technologies: evidence for the allosteric inhibition of a protein – protein interaction.
  54. (1997). Bioactive peptide design based on protein surface epitopes. A cyclic heptapeptide mimics CD4 domain 1 CC’ loop and inhibits CD4 biological function.
  55. (1999). Borysenko CW. Small molecule cytokine mimetics. Chem Biol.
  56. Brefeldin A: the advantage of being uncompetitive.
  57. Complementarity of structure ensembles in protein–protein binding.
  58. Computational alanine scanning mutagenesis – an improved methodological approach.
  59. (2004). Computational alanine scanning of protein–protein interfaces. Sci STKE.
  60. Computational identification of inhibitors of protein–protein interactions. Curr Top Med Chem.
  61. (2005). Computational methods for protein–protein interaction and their application. Curr Protein Pept Sci.
  62. (2008). Computational prediction of protein–protein interactions. Mol Biotechnol.
  63. Computer analysis of protein–protein interaction.
  64. Conservation of polar residues as hot spots at protein interfaces.
  65. (1994). creation, and characterization of a stable, monomeric triosephosphate isomerase.
  66. (1990). Crystal structure of an HIV-binding recombinant fragment of human CD4.
  67. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution.
  68. (1999). Cutting edge: a small molecule antagonist of LFA-1-mediated cell adhesion.
  69. (1994). Design and synthesis of a biologically active antibody mimic based on an antibody-antigen crystal structure.
  70. (1991). Design and synthesis of a mimetic from an antibody complementarity-determining region.
  71. (1998). Design and synthesis of small molecule interleukin-1 receptor antagonists based on a benzene template. Drug Des Discov.
  72. (2001). Design of inhibitors of Ras–Raf interaction using a computational combinatorial algorithm. Protein Eng.
  73. Designed molecules that fold to mimic protein secondary structures. Curr Opin Chem Biol.
  74. Designing cell-permeant phosphopeptides to modulate intracellular signaling pathways.
  75. Designing cytokine variants by phage-display. Comb Chem High Throughput Screen.
  76. Designing small-molecule switches for protein–protein interactions.
  77. Detailed ab initio prediction of lysozymeantibody complex with 1.6 A accuracy.
  78. (1999). Detecting protein function and protein–protein interactions from genome sequences.
  79. (2000). DIP: the database of interacting proteins. Nucleic Acids Res.
  80. Discovering motif pairs at interaction sites from protein sequences on a proteome-wide scale.
  81. (2000). Discovery and evaluation of potent, cysteinebased alpha4beta1 integrin antagonists. Bioorg Med Chem Lett.
  82. (2000). Discovery and evaluation of potent, tyrosine-based alpha4beta1 integrin antagonists. Bioorg Med Chem Lett.
  83. (1997). Discovery of 3-aminobenzyloxycarbonyl as an N-terminal group conferring high affinity to the minimal phosphopeptide sequence recognized by the Grb2-SH2 domain.
  84. Discovery of a potent small molecule IL-2 inhibitor through fragment assembly.
  85. (1999). Discovery of a small molecule insulin mimetic with antidiabetic activity in mice.
  86. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53.
  87. Discovery of SB-497115, a small-molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia.
  88. (1990). Distance-constrained molecular docking by simulated annealing. Protein Eng.
  89. Docking and scoring protein complexes: CAPRI 3rd Edition.
  90. (1992). Docking by least-squares fitting of molecular surface patterns.
  91. Docking enzyme-inhibitor complexes using a preference-based free-energy surface.
  92. Docking unbound proteins using shape complementarity, desolvation, and electrostatics.
  93. (1997). Electrostatic influence on the kinetics of ligand binding to acetylcholinesterase. Distinctions between active center ligands and fasciculin.
  94. (1999). Emergent properties of networks of biological signaling pathways.
  95. Energy minimization in low-frequency normal modes to efficiently allow for global flexibility during systematic protein–protein docking.
  96. ESCHER: a new docking procedure applied to the reconstruction of protein tertiary structure.
  97. Examination of shape complementarity in docking of unbound proteins.
  98. (2001). Experimental and computational mapping of the binding surface of a crystalline protein. Protein Eng.
  99. Exploring protein–protein interactions with phage display.
  100. (1996). Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol.
  101. Flexible protein–protein docking. Curr Opin Struct Biol.
  102. (1994). From peptide to nonpeptide. 1. The elucidation of a bioactive conformation of the arginine-glycine-aspartic acid recognition sequence.
  103. (1994). From peptide to nonpeptide. 2. The de novo design of potent, non-peptidal inhibitors of platelet aggregation based on a benzodiazepinedione scaffold.
  104. Functionality maps of binding sites: a multiple copy simultaneous search method.
  105. Genome-wide analysis of vaccinia virus protein–protein interactions.
  106. Global efforts in structural genomics.
  107. HADDOCK: a protein–protein docking approach based on biochemical or biophysical information.
  108. High-confidence prediction of global interactomes based on genome-wide coevolutionary networks.
  109. (1998). High-throughput screening of historic collections: observations on file size, biological targets, and file diversity. Biotechnol Bioeng.
  110. High-throughput screening strategies to identify inhibitors of protein–protein interactions.
  111. Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors.
  112. (1996). Hydrogen bonding and molecular surface shape complementarity as a basis for protein docking.
  113. Hydrophobic docking: a proposed enhancement to molecular recognition techniques.
  114. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis.
  115. (1994). ICM – A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation.
  116. Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction.
  117. (1997). Identification of a small molecule inhibitor of the IL2/IL2rα receptor interaction which binds to IL-2. J Am Chem Soc.
  118. Identification of hot-spot residues in protein–protein interactions by computational docking.
  119. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site.
  120. Identification of novel extracellular signal-regulated kinase docking domain inhibitors.
  121. Identification of novel fragment compounds targeted against the pY pocket of v-Src SH2 by computational and NMR screening and thermodynamic evaluation.
  122. Identification of protein– protein interaction sites from docking energy landscapes.
  123. (1998). Identification of the CD8 DE loop as a surface functional epitope. Implications for major histocompatibility complex class I binding and CD8 inhibitor design.
  124. (2006). Identifying interaction motifs in CK2beta – a ubiquitous kinase regulatory subunit. Trends Biochem Sci.
  125. Improved side-chain modeling for protein–protein docking. Protein Sci.
  126. (2008). In silico-in vitro screening of protein–protein interactions: towards the next generation of therapeutics. Curr Pharm Biotechnol.
  127. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.
  128. Increasing confidence of protein interactomes using network topological metrics.
  129. Inhibiting protein–protein interactions: a model for antagonist design.
  130. (1998). Inhibiting the assembly of protein–protein interfaces. Curr Opin Chem Biol.
  131. (1997). Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism.
  132. (1998). Inhibition of HIV-1 protease by a subunit of didemnaketal A. J Am Chem Soc.
  133. (1994). Inhibition of human immunodeficiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain.
  134. Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein–protein interactions.
  135. Integrating statistical pair potentials into protein complex prediction.
  136. Interaction-site prediction for protein complexes: a critical assessment.
  137. Interactome: gateway into systems biology. Hum Mol Genet. 2005;14(Spec No 2):R171–R181.
  138. (1995). Interface peptides as structure-based human immunodeficiency virus reverse transcriptase inhibitors.
  139. (2007). ISIS: interaction sites identified from sequence.
  140. Lead validation and SAR development via chemical similarity searching; application to compounds targeting the pY+3 site of the SH2 domain of p56lck.
  141. (2005). Library design for fragment based screening. Curr Top Med Chem.
  142. (1999). Lipopeptides as dimerization inhibitors of HIV-1 protease. Biol Chem.
  143. Locating interaction sites on proteins: the crystal structure of thermolysin soaked in 2% to 100% isopropanol.
  144. (1996). Macromolecular versus small-molecule therapeutics: drug discovery, development and clinical considerations. Trends Biotechnol.
  145. (1999). Mimicry of erythropoietin by a nonpeptide molecule.
  146. (1997). Minimized proteins. Curr Opin Struct Biol.
  147. Mining literature for protein– protein interactions.
  148. (2000). MIPS: a database for genomes and protein sequences. Nucleic Acids Res.
  149. Modeling side-chains using molecular dynamics improve recognition of binding region in CAPRI targets.
  150. (1997). Modelling protein docking using shape complementarity, electrostatics and biochemical information.
  151. (1996). Molecular docking programs successfully predict the binding of a betalactamase inhibitory protein to TEM-1 beta-lactamase. Nat Struct Biol.
  152. (1992). Molecular surface recognition: determination of geometric fit between proteins and their ligands by correlation techniques.
  153. (1993). Monoclonal antibodies in cancer therapy. Curr Opin Immunol.
  154. (1987). Monte Carlo-minimization approach to the multiple-minima problem in protein folding.
  155. (1993). Multiple copy simultaneous search and construction of ligands in binding sites: application to inhibitors of HIV-1 aspartic proteinase.
  156. (1992). New algorithm to model protein–protein recognition based on surface complementarity. Applications to antibody-antigen docking.
  157. New methodology for computer-aided modelling of biomolecular structure and dynamics. 1. Non-cyclic structures.
  158. New methodology for computeraided modelling of biomolecular structure and dynamics. 2. Local deformations and cycles.
  159. (2000). Non-amide-based combinatorial libraries derived from N-Boc iminodiacetic acid: Solution-phase synthesis of piperazinone libraries with activity against LEF-1ß/-catenin-mediated transcription. Helv Chim Acta.
  160. Optimal docking area: a new method for predicting protein–protein interaction sites.
  161. Optimal protocol and trajectory visualization for conformational searches of peptides and proteins. J Mol Biol.
  162. Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold.
  163. (1997). Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine.
  164. (1999). Peptide and peptidomimetic inhibitors of VLA-4. Exp Opin Ther Patents.
  165. (2000). Peptide and protein recognition by designed molecules. Chem Rev.
  166. Peptides identify the critical hotspots involved in the biological activation of the insulin receptor.
  167. Peptidic modulators of protein–protein interactions: progress and challenges in computational design.
  168. (1996). Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase with improved in vivo antiviral activity.
  169. Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha.
  170. (2008). PIE: an online prediction system for protein–protein interactions from text. Nucleic Acids Res.
  171. (2009). Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells.
  172. (2008). Predicting 3D structures of protein–protein complexes. Curr Pharm Biotechnol.
  173. (2008). Predicting biological networks from genomic data. FEBS Lett.
  174. Predicting protein–protein interactions using signature products.
  175. (1996). Prediction of protein complexes using empirical free energy functions. Protein Sci.
  176. Prediction of protein interaction sites from sequence profile and residue neighbor list.
  177. Prediction of protein–protein interaction sites using patch analysis. J Mol Biol.
  178. (2004). Prediction of protein–protein interactions: the CAPRI experiment, its evaluation and implications. Curr Opin Struct Biol.
  179. (2004). PreSPI: a domain combination based prediction system for protein–protein interaction. Nucleic Acids Res.
  180. Principles of docking: An overview of search algorithms and a guide to scoring functions.
  181. (1996). Principles of protein–protein interactions.
  182. (1975). Principles of protein–protein recognition.
  183. Probing the effect of poitn mutations at protein – protein interfaces with free energy calculations.
  184. Progress of structural genomics initiatives: an analysis of solved target structures.
  185. ProMate: a structure based prediction program to identify the location of protein–protein binding sites.
  186. (1991). Protein docking and complementarity.
  187. (1995). Protein docking for low-resolution structures. Protein Eng.
  188. Protein docking using a genetic algorithm.
  189. Protein docking using spherical polar Fourier correlations.
  190. Protein interaction mapping in C. elegans using proteins involved in vulval development.
  191. (1999). Protein interaction maps for complete genomes based on gene fusion events.
  192. (1998). Protein interactions in solution characterized by light and neutron scattering: comparison of lysozyme and chymotrypsinogen.
  193. Protein-ligand docking as an energy optimization problem.
  194. Protein–protein Docking Benchmark 2.0: an update.
  195. Protein–protein Docking Benchmark version 3.0.
  196. (2009). Protein–protein docking dealing with the unknown.
  197. Protein–protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations.
  198. (2007). Protein–protein interaction hotspots carved into sequences. PLoS Comput Biol.
  199. Protein–protein interaction investigated by steered molecular dynamics: the TCR-pMHC complex.
  200. (1995). Protein–protein interactions: a review of protein dimer structures. Prog Biophys Mol Biol.
  201. Protein–protein interactions: structurally conserved residues distinguish between binding sites and exposed protein surfaces.
  202. Protein–protein recognition analyzed by docking simulation.
  203. (1997). Proteinminus signProtein Interactions: Interface Structure, Binding Thermodynamics, and Mutational Analysis. Chem Rev.
  204. (1994). PUZZLE: a new method for automated protein docking based on surface shape complementarity.
  205. pyDock: electrostatics and desolvation for effective scoring of rigid-body protein–protein docking.
  206. (1998). Rapid refinement of protein interfaces incorporating solvation: application to the docking problem.
  207. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor.
  208. (2000). Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol.
  209. (1981). Real-time color graphics in studies of molecular interactions.
  210. Recognition and cooperation between the ATP-dependent RNA helicase RhlB and ribonuclease RNase E.
  211. Scoring docked conformations generated by rigid-body protein–protein docking.
  212. Screening outside the catalytic site: inhibition of macromolecular interactions through structure-based virtual ligand screening experiments.
  213. (2009). Second generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults. J Oncol Pharm Pract.
  214. (1999). Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of nonnatural binding elements. Nat Struct Biol.
  215. Selective binding and oligomerization of the murine granulocyte colony-stimulating factor receptor by a low molecular weight, nonpeptidyl ligand.
  216. Selective disruption of protein aggregation by cyclodextrin dimers.
  217. (2006). Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chem Biol.
  218. (1996). Sensing the heat: the application of isothermal titration calorimetry to thermodynamic studies of biomolecular interactions. Chem Biol.
  219. (1997). SH3 domains and drug design: ligands, structure, and biological function.
  220. (1986). Shape complementarity at the hemoglobin alpha 1 beta 1 subunit interface.
  221. (2001). Similarity of phylogenetic trees as indicator of protein–protein interaction. Protein Eng.
  222. Small molecule ligands define a binding site on the immune regulatory protein B7.1.
  223. (1996). Small peptides as potent mimetics of the protein hormone erythropoietin.
  224. (2004). Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell.
  225. (2004). Small-molecule inhibitors of protein–protein interactions: progressing towards the dream. Nat Rev Drug Discov.
  226. (1991). Soft docking”: matching of molecular surface cubes.
  227. (2002). Soft protein–protein docking in internal coordinates. Protein Sci.
  228. (2001). Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 1: design of potent and specific 3,9-di azaspiro[5.5]undecanes. Bioorg Med Chem Lett.
  229. (2001). Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 2: design of potent antagonists containing the 3-azaspiro[5.5]undecanes. Bioorg Med Chem Lett.
  230. (1998). Src homology-2 domains: structure, mechanisms, and drug discovery.
  231. Stable “zeta” peptides that act as potent antagonists of the high-affinity IgE receptor.
  232. (1998). Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity.
  233. Structural and functional characterization of binding sites in metallocarboxypeptidases based on optimal docking area analysis.
  234. (2000). Structural chemistry and therapeutic intervention of protein– protein interactions in immune response, human immunodeficiency virus entry, and apoptosis. Pharmacol Ther.
  235. (1998). Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain.
  236. (2000). Structure-based design of compounds inhibiting Grb2-SH2 mediated protein–protein interactions in signal transduction pathways. Curr Pharm Des.
  237. (1999). Structure-based design, synthesis, and X-ray crystallography of a highaffinity antagonist of the Grb2-SH2 domain containing an asparagine mimetic.
  238. subunit interfaces and interior of oligomeric proteins.
  239. Successful discrimination of protein interactions.
  240. Surface recognition of a protein using designed transition metal complexes.
  241. synthesis, and application of a protein A mimetic.
  242. (1998). Synthetic interface peptides as inactivators of multimeric enzymes: inhibitory and conformational properties of three fragments from Lactobacillus casei thymidylate synthase.
  243. Synthetic peptide GRGDS induces dissociation of alpha-actinin and vinculin from the sites of focal contacts.
  244. (2000). Systematic and large-scale two-hybrid screens. Curr Opin Microbiol.
  245. (1991). Systematic mutational analyses of protein–protein interfaces. Methods Enzymol.
  246. Targeting the dimerization interface for irreversible inhibition of HIV-1 protease. Bioorg Med Chem Lett.
  247. (2004). Tethering: fragment-based drug discovery. Annu Rev Biophys Biomol Struct.
  248. (1999). The atomic structure of protein–protein recognition sites.
  249. (1992). The computer program LUDI: A new method for the de novo design of enzyme inhibitors. J Comput Aided Mol Des.
  250. The crystal structure of an engineered monomeric triosephosphate isomerase, monoTIM: the correct modelling of an eight-residue loop.
  251. The crystal structure of the BAR domain from human Bin1/amphiphysin II and its implications for molecular recognition.
  252. (1996). The inhibition of human immunodeficiency virus proteases by ‘interface peptides’. Antiviral Res.
  253. (2007). The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res.
  254. The interactome: predicting the protein– protein interactions in cells.
  255. (2009). The multi-copy simultaneous search methodology: a fundamental tool for structure-based drug design. J Comput Aided Mol Des.
  256. The Protein Data Bank: a computer-based archival file for macromolecular structures.
  257. The protein–protein interaction map of Helicobacter pylori.
  258. The relationship between the flexibility of proteins and their conformational states on forming protein–protein complexes with an application to protein–protein docking.
  259. (2000). The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core. Bioorg Med Chem.
  260. (1990). The structure of protein–protein recognition sites.
  261. The use of peptides in Diogenesis: a novel approach to drug discovery and phenomics.
  262. (2000). The use of TNF family ligands and receptors and agents which modify their interaction as therapeutic agents. Curr Drug Targets.
  263. (2000). The yeast proteome database (YPD) and Caenorhabditis elegans proteome database (WormPD): comprehensive resources for the organization and comparison of model organism protein information. Nucleic Acids Res.
  264. Three-dimensional cluster analysis identifies interfaces and functional residue clusters in proteins.
  265. Toward a protein–protein interaction map of the budding yeast: A comprehensive system to examine two-hybrid interactions in all possible combinations between the yeast proteins.
  266. Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an alpha-helix.
  267. (1998). Towards protein surface mimetics. Curr Med Chem.
  268. Tubulin-interactive natural products as anticancer agents (1).
  269. Two-hybrid technologies in proteomics research.
  270. (2002). Unraveling hot spots in binding interfaces: progress and challenges. Curr Opin Struct Biol.
  271. (1996). What can we learn from molecular recognition in protein-ligand complexes for the design of new drugs? Angew Chem Int Ed Engl.
  272. WHISCY: what information does surface conservation yield? Application to data-driven docking.
  273. (2006). Yeast two-hybrid contributions to interactome mapping. Curr Opin Biotechnol.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.